We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Enhertu

News List

AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation pharmatimes
May 19, 2020
AstraZeneca's and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with a particular form of lung cancer.
US nod for Lynparza in HRD-positive advanced ovarian cancer pharmatimes
May 12, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies worldpharmanews
December 23, 2019
The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable ...

Previous page 1 2 Next page